Biomaterial Database

[Conservative treatment of peripheral arterial occlusive diseases]. 1978

J Hoffmann

The therapeutical effect and tolerance of Defluina was studied in a selective open trial of 24 patients suffering from peripheral arterial diseases in Fontaine's stage I and II. All patients were treated with Defluina, 30 drops three times a day during a period of six weeks. From the statistically significant improvement of the different control parameters it can be concluded that peripheral arterial circulation has increased considerably in the course of the Defluina treatment. The preparation was always well tolerated, no side-effects were observed.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004087	Dihydroergotamine	A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.	Agit,Angionorm,Clavigrenin,D-Tamin Retard L.U.T.,D.H.E. 45,DET MS,DHE-45,DHE-Puren,DHE-Ratiopharm,Dihydergot,Dihydroergotamin AL,Dihydroergotamine Mesylate,Dihydroergotamine Methanesulfonate,Dihydroergotamine-Sandoz,Dihytamin,Erganton,Ergomimet,Ergont,Ergotam Von Ct,Ikaran,Migranal,Orstanorm,Seglor,Tamik,Verladyn,D Tamin Retard L.U.T.,DHE 45,DHE Puren,DHE Ratiopharm,DHE45,Dihydroergotamine Sandoz,Mesylate, Dihydroergotamine,Methanesulfonate, Dihydroergotamine,Von Ct, Ergotam
D004088	Dihydroergotoxine	A mixture of three different hydrogenated derivatives of ERGOTAMINE: DIHYDROERGOCORNINE; DIHYDROERGOCRISTINE; and DIHYDROERGOCRYPTINE. Dihydroergotoxine has been proposed to be a neuroprotective agent and a nootropic agent. The mechanism of its therapeutic actions is not clear, but it can act as an alpha-adrenergic antagonist and a dopamine agonist. The methanesulfonate salts of this mixture of alkaloids are called ERGOLOID MESYLATES.	Co-Dergocrine,Ergot Alkaloids, Hydrogenated,Dihydroergotoxin,Alkaloids, Hydrogenated Ergot,Hydrogenated Ergot Alkaloids
D004338	Drug Combinations	Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.	Drug Combination,Combination, Drug,Combinations, Drug
D004341	Drug Evaluation	Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.	Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly